DOCK2 and neoplasm: Interestingly, we did not observe differences in the levels of kynurenine but the downstream metabolite xanthurenate was elevated in Vil Apc Dock2 tumours suggesting a rapid conversion of kynurenine via this pathway (Fig. 6F–H).